Known safety concerns, contraindications, and risk factors.
Active malignancy
MOTS-c influences mitochondrial biogenesis, which may promote tumor growth in patients with active cancer.
Concurrent Metformin use
MOTS-c combined with Metformin may cause cumulative AMPK activation, risking excessive metabolic effects.
Pregnancy or adolescence
No safety data exists for use of these peptides during pregnancy or in adolescents.
Kidney disease
SS-31/Elamipretide may pose additional risks in patients with kidney disease.
WADA-tested athlete status
GW501516, MOTS-c, Tesamorelin, AICAR, BPC-157, and TB-500 are all WADA prohibited substances.